北美呼吸诊断市场 – 行业趋势和 2030 年预测

北美呼吸诊断市场分析和规模

北美地区受到慢性病负担的影响很大，尤其是在疫情之后，这增加了呼吸诊断的采用。慢性病是世界主要的医疗保健问题之一，每年导致约 4000 万人死亡，其中 850 万人来自亚洲。技术进步、设备便携性和易操作性预计将促进增长。呼吸系统疾病发病率的上升引起了人们对准确疾病诊断的极大关注，从而促进了呼吸诊断市场的增长。

Data Bridge Market Research 分析了 2023-2030 年预测期内呼吸诊断市场的增长率。在上述预测期内，呼吸诊断市场的预期复合年增长率趋于 7.60% 左右。2022 年市场价值为 34.8669 亿美元，到 2030 年将增长至 62.6486 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

北美呼吸诊断市场范围和细分

​​​​​​​

Market Definition

Respiratory diagnostics are the type of medical products and technologies that are widely used to diagnose the respiratory diseases and disorders in the patients. Respiratory diagnostics are effective since it can diagnose the diseases at an early stage. It involve procedures such as computed tomography, spirometry, oximetry, chest X-ray, transcutaneous carbon dioxide monitoring, sniff nasal inspiratory pressure (SNIP) among several other types.

North America Respiratory Diagnostics Market Dynamics

Drivers

• Increasing Adoption of Self Testing Products

Growing adoption of self-testing products and point-of-care products may boost the growth. For instance, Abbott received EUA for introducing the BinaxNOW COVID-19 Ag Card rapid test in 2020, which delivers results at home in 15 minutes. As of August 2021, about 59 at-home testing products have been authorized by the U.S. FDA for COVID-19 diagnosis that uses home-collected specimens. In addition to this, 6 antigens Over the Counter (OTC) at-home tests, 3 antigen prescription at-home tests, 2 molecular OTC at-home tests, and 1 molecular prescription at-home test were also authorized by the U.S. FDA for self-testing of COVID-19. Thus, this increasing prevalence demands increased diagnostics which boost the market growth.

• Increased Rate of Saliva Sample

The saliva sample type is expected to witness a huge growth rate during the forecast period. This growth is due to the growing use of samples in testing along with an urgent need for non-invasive tests. In a study published in May 2020, several researchers established the sensitivity and specificity of the saliva sample test, which were found to be about 84.2% and 98.9%, respectively. Consequently, market players started developing and commercializing no-swabs saliva-based tests. Thus, this factor boosts the market growth.

Opportunities

• Increased Rate of Tuberculosis

The increasing rate of tuberculosis in the North America region is boosting the growth of the market. In 2021, the U.S. reported 7,882 TB cases and an incidence rate of 2.4 cases per 100,000 persons. TB data from 2021 show a rebound in the number of reported cases of TB disease in the U.S. Thus, all these factors boost the market growth.

• Growing Product Launches and Collaborations

Numerous product launches, partnership and agreement are initiated by many companies globally, which are also increasing the respiratory diagnostics market. For instance, Cipla Limited launched Spirofy, India's first pneumotach-based portable, wireless Spirometer, on World COPD Day in November 2021. Thus, these kinds of launches associated with the respiratory diagnostics boost the market growth.

Restraints/Challenges

• High Cost of Diagnostic Instruments

The increased expenditure required for the installation of these instruments hamper the market growth. Many of the diagnostic equipment are very high in cost, becoming unaffordable for many underdeveloped countries. Numerous market players make huge investments in installing new and advanced machines to increase the process and in return the cost is increased. Thus, this factor hamper the market growth.

This North America respiratory diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the North America respiratory diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, F. Hoffmann-La Roche Ltd received emergency use approval from the U.S. FDA for testing cobas SARS-CoV-2 and influenza A/B used in the F600 / 80,000 system. As a result of the company’s approval of this emergency use, SARC has increased demand for its diagnostic products for Covid, which has increased sales and revenue.
• In 2020, F. Hoffmann-La Roche Ltd received Emergency Use Authorization (EUA) approval from the American Food and Drug Administration (FDA) for a product, Alexis Anti-SARS-CoV-2 Antibody Test. The FDA approval obtained by the company during the emergence of COVID-19 will surge its revenue and sales in the market.

North America Respiratory Diagnostics Market Scope

The North America respiratory diagnostics market is segmented on the basis of product and services, test type, diseases, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

• Instruments and Devices
• Assays and Reagents
• Services and Software

Test Type

• Traditional Diagnostic Tests
• Mechanical Tests
• Imaging Tests
• Molecular Diagnostic Tests

Diseases

• Chronic Obstructive Pulmonary Disease (COPD)
• Lung Cancer
• Asthma
• 结核
• 支气管炎
• 肺纤维化
• 其他疾病

最终用户

• 医院/临床实验室
• 医生办公室
• 参考实验室
• 其他的

分销渠道

• 直接招标
• 零售销售
• 其他

 北美呼吸诊断市场区域分析/见解

对北美呼吸诊断市场进行了分析，并按上述产品和服务、测试类型、疾病、最终用户和分销渠道提供了市场规模洞察和趋势。

呼吸诊断市场报告涉及的主要国家 是美国、加拿大和墨西哥。

美国正引领市场增长，因为其检测率高、政府采取积极措施、医疗基础设施大幅改善、技术进步，以及主要市场参与者不断增加。此外，政府的优惠举措和报销政策可能会推动该地区的增长。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

呼吸诊断还为您提供每个国家/地区资本设备医疗支出增长、呼吸诊断市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对呼吸诊断市场的影响的详细市场分析。数据涵盖 2011-2021 年的历史时期。

竞争格局和北美呼吸诊断市场份额分析

北美呼吸诊断市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对北美呼吸诊断市场的关注有关。

北美呼吸诊断市场的主要参与者包括：

• BD（美国）
• COSMED srl（意大利）
• 雅培（美国）
• 日本光电株式会社（日本）
• Drägerwerk AG & Co. KGaA（德国）
• Bio-Rad Laboratories, Inc.（美国）
• 赛默飞世尔科技公司（美国）
• 通用电气（美国）
• Koninklijke Philips NV（荷兰）
• 美敦力（爱尔兰）
• F. Hoffmann-La Roche Ltd（瑞士）
• MGC 诊断公司（美国）
• Masimo（美国）
• 生物梅里埃（法国）
• Carestream Health（美国）
• VYAIRE（美国）
• Seegene Inc.（韩国）
• ResMed（美国）

SKU-57097